NCT07590648Not yet recruitingPhase 4
Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia
Phase IV, Randomized, Open Label, Parallel Groups Clinical Trial for Evaluating the Early Stop of Antibiotic Treatment in High-risk Febrile Neutropenic Oncohaematological Paediatric Patients (e-STOP 2)
Source: ClinicalTrials.gov · Last updated 15 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether stopping antibiotic treatment early is safe in paediatric patients with cancer who develop high-risk febrile neutropenia but show good clinical evolution and low biomarker levels 48-72 hours after the episode. The main questions it aims to answer are: Is early discontinuation of antibiotics as safe as the standard strategy in terms of preventing invasive bacterial infections (such as sepsis, microbiologically documented infection, ICU admission, or death)? Does this strategy reduce the number of days on antibiotics without increasing infection-related complications? Researchers will compare early antibiotic discontinuation with the standard care strategy to see whether the early-stop approach provides similar safety while reducing antibiotic exposure. Participants will: Receive standard initial antibiotic therapy for febrile neutropenia. Undergo clinical and biomarker evaluations (including CRP and PCT). Be randomly assigned to: Experimental group: early discontinuation of antibiotics, or Control group: continuation of the standard antibiotic strategy. Be followed for 28 days after randomisation to monitor safety outcomes and treatment effects.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 136 (estimated)
- First submitted
- 16 Feb 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Diseases
- Childhood cancers
- NCT number
- NCT07590648
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 136
- From 1 Jun 2026 to the primary completion date, 1 Jul 2028
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition which, in the investigator's opinion, makes study participation unsuitable for the patient or could limit, prevent, or confound the assessments planned in the protocol.
Other
- Antibiotic treatment at the time of the FN episode different from that used prophylactically.
- Empirical antibiotic treatment different from that recommended in international guidelines.
- Patient with poor clinical evolution during the first 12 hours (hemodynamic instability, PICU admission, death).
- Active participation in the same study at the onset of the current FN episode.
- Active participation in another clinical trial that, in the investigators' opinion, may interfere with the assessment of the results.
- Female patients who are pregnant or breastfeeding
Who the study is looking for
- Male and female patients ≤18 years of age expected to develop prolonged neutropenia (\>7 days), with:
- Acute myeloblastic leukaemia at any phase of chemotherapy
- Acute lymphoblastic leukaemia in induction, consolidation, or intensification phases
- Biphenotypic leukaemia at any phase of chemotherapy
- Lymphoblastic lymphoma in induction and consolidation phases
- B-cell and anaplastic lymphoma receiving high-intensity chemotherapy
- Solid tumours receiving high-intensity chemotherapy
- Relapsed leukaemia at any phase of treatment
- Episode of febrile neutropenia (FN), defined as a single axillary temperature ≥38.0°C in a patient with an absolute neutrophil count (ANC) \<500 neutrophils/mm³, or expected to fall below this value within the next 48-72 hours.
- Antibiotic treatment initiated for the current FN episode (routine antimicrobial prophylaxis is allowed, as well as teicoplanin 3 days/week for patients with AML included in the CHIP-AML-2022 protocol and therefore in the Pro-teico study).
- Low risk of invasive bacterial infection (IBI) at the start of the FN episode. Patients must meet all of the following:
- CRP \<9 mg/dL
- PCT \<0.5 ng/mL
- Absence of hypotension
- No microbiologically documented bacterial infection 48-72 hours after the FN episode.
- Good clinical evolution 48-72 hours after the FN episode, defined as:
- Afebrile for \>48 hours (axillary temperature \<38°C)
- Haemodynamically stable
- Stable paediatric early warning score (PEWS)
- CRP \<5 mg/dL, or CRP \<9 mg/dL and PCT \<0.5 ng/mL, with decreasing trend at the time of randomisation (values will be assessed on day 3 and day 5 after the FN episode).
- ANC \<500 neutrophils/mm³ at the time of randomisation.
- Signed informed consent from the patient and/or parent(s)/legal representative(s).
- Patient and/or parent(s)/legal representative(s) must have sufficient reading and writing skills to understand and provide consent to participate in the study.
- Patient and/or parent(s)/legal representative(s) must be considered reliable and capable of adhering to the protocol.
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Hospital Sant Joan De Deu Coordinator of this site? Confirm its status | Esplugues de Llobregat | Spain | Unknown status |
| Hospital Universitario La Paz Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
| Hospital Infantil Universitario Nino Jesus Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.